Moreover, the stratification of patients according to CD103 or CD3 counts in the tumor, highlighted striking differences according to overall survival: the CD3highCD103high group had a 5-years survival rate at 90%, the CD3lowCD103high at 63% and the CD3lowCD103low at 0%, thus demonstrating the crucial presence of TILs and the potential power of the CD103 marker to predict patient outcome (43). Here, ITGAE is linked to neoplasm.